ENTA Enanta Pharmaceuticals Inc

Price (delayed)

$51.72

Market cap

$1.04B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.89

Enterprise value

$996.3M

Sector: Healthcare
Industry: Biotechnology

Highlights

Enanta Pharmaceuticals's quick ratio has decreased by 19% YoY but it has increased by 7% QoQ
The debt has grown by 8% from the previous quarter but it has contracted by 4.4% YoY
ENTA's net income has dropped by 60% since the previous quarter
The EPS has dropped by 60% since the previous quarter

Key stats

What are the main financial stats of ENTA
Market
Shares outstanding
20.17M
Market cap
$1.04B
Enterprise value
$996.3M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.3
Price to sales (P/S)
10.22
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.8
Earnings
Revenue
$101.65M
EBIT
-$63.54M
EBITDA
-$59.93M
Free cash flow
-$21.31M
Per share
EPS
-$2.89
Free cash flow per share
-$1.06
Book value per share
$22.51
Revenue per share
$5.06
TBVPS
$23.94
Balance sheet
Total assets
$481.01M
Total liabilities
$29.02M
Debt
$8.72M
Equity
$452M
Working capital
$422.9M
Liquidity
Debt to equity
0.02
Current ratio
19.35
Quick ratio
18.16
Net debt/EBITDA
0.78
Margins
EBITDA margin
-59%
Gross margin
100%
Net margin
-57%
Operating margin
-65.7%
Efficiency
Return on assets
-11.6%
Return on equity
-12.4%
Return on invested capital
-15.7%
Return on capital employed
-13.9%
Return on sales
-62.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ENTA stock price

How has the Enanta Pharmaceuticals stock price performed over time
Intraday
0.54%
1 week
-1.5%
1 month
8.5%
1 year
0.56%
YTD
22.85%
QTD
22.85%

Financial performance

How have Enanta Pharmaceuticals's revenue and profit performed over time
Revenue
$101.65M
Gross profit
$101.65M
Operating income
-$66.81M
Net income
-$57.94M
Gross margin
100%
Net margin
-57%
The operating margin has plunged by 93% from the previous quarter
The net margin has plunged by 93% from the previous quarter
The company's operating income has shrunk by 60% QoQ
ENTA's net income has dropped by 60% since the previous quarter

Growth

What is Enanta Pharmaceuticals's growth rate over time

Valuation

What is Enanta Pharmaceuticals stock price valuation
P/E
N/A
P/B
2.3
P/S
10.22
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.8
The EPS has dropped by 60% since the previous quarter
ENTA's P/B is 21% below its 5-year quarterly average of 2.9 but 15% above its last 4 quarters average of 2.0
The equity has decreased by 6% YoY
Enanta Pharmaceuticals's revenue has decreased by 46% YoY and by 17% from the previous quarter
The price to sales (P/S) is 44% higher than the last 4 quarters average of 7.1 and 23% higher than the 5-year quarterly average of 8.3

Efficiency

How efficient is Enanta Pharmaceuticals business performance
The return on sales has dropped by 119% since the previous quarter
ENTA's return on invested capital has dropped by 89% since the previous quarter
Enanta Pharmaceuticals's return on equity has shrunk by 63% QoQ
Enanta Pharmaceuticals's ROA has plunged by 61% from the previous quarter

Dividends

What is ENTA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ENTA.

Financial health

How did Enanta Pharmaceuticals financials performed over time
Enanta Pharmaceuticals's quick ratio has decreased by 19% YoY but it has increased by 7% QoQ
Enanta Pharmaceuticals's current ratio has decreased by 16% YoY but it has increased by 7% from the previous quarter
The debt is 98% less than the equity
The debt has grown by 8% from the previous quarter but it has contracted by 4.4% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.